Dosimetry-Driven Quality Measure of Brain Pseudo Computed Tomography Generated From Deep Learning for MRI-Only Radiation Therapy Treatment Planning.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
01 11 2020
Historique:
received: 15 11 2019
revised: 21 04 2020
accepted: 05 05 2020
pubmed: 18 5 2020
medline: 10 4 2021
entrez: 18 5 2020
Statut: ppublish

Résumé

This study aims to evaluate the impact of key parameters on the pseudo computed tomography (pCT) quality generated from magnetic resonance imaging (MRI) with a 3-dimensional (3D) convolutional neural network. Four hundred two brain tumor cases were retrieved, yielding associations between 182 computed tomography (CT) and T1-weighted MRI (T1) scans, 180 CT and contrast-enhanced T1-weighted MRI (T1-Gd) scans, and 40 CT, T1, and T1-Gd scans. A 3D CNN was used to map T1 or T1-Gd onto CT scans and evaluate the importance of different components. First, the training set size's influence on testing set accuracy was assessed. Moreover, we evaluated the MRI sequence impact, using T1-only and T1-Gd-only cohorts. We then investigated 4 MRI standardization approaches (histogram-based, zero-mean/unit-variance, white stripe, and no standardization) based on training, validation, and testing cohorts composed of 242, 81, and 79 patients cases, respectively, as well as a bias field correction influence. Finally, 2 networks, namely HighResNet and 3D UNet, were compared to evaluate the architecture's impact on the pCT quality. The mean absolute error, gamma indices, and dose-volume histograms were used as evaluation metrics. Generating models using all the available cases for training led to higher pCT quality. The T1 and T1-Gd models had a maximum difference in gamma index means of 0.07 percentage point. The mean absolute error obtained with white stripe was 78 ± 22 Hounsfield units, which slightly outperformed histogram-based, zero-mean/unit-variance, and no standardization (P < .0001). Regarding the network architectures, 3%/3 mm gamma indices of 99.83% ± 0.19% and 99.74% ± 0.24% were obtained for HighResNet and 3D UNet, respectively. Our best pCTs were generated using more than 200 samples in the training data set. Training with T1 only and T1-Gd only did not significantly affect performance. Regardless of the preprocessing applied, the dosimetry quality remained equivalent and relevant for potential use in clinical practice.

Identifiants

pubmed: 32417412
pii: S0360-3016(20)31130-5
doi: 10.1016/j.ijrobp.2020.05.006
pii:
doi:

Substances chimiques

Contrast Media 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

813-823

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Emilie Alvarez Andres (E)

U1030 Molecular Radiotherapy, Paris-Sud University - Gustave Roussy - Inserm - Paris-Saclay University, Villejuif, France; TheraPanacea, Paris, France; Department of Medical Physics, Gustave Roussy - Paris-Saclay University, Villejuif, France.

Lucas Fidon (L)

TheraPanacea, Paris, France; MICS Laboratory, CentraleSupélec, Paris-Saclay University, Gif-sur-Yvette, France.

Maria Vakalopoulou (M)

MICS Laboratory, CentraleSupélec, Paris-Saclay University, Gif-sur-Yvette, France.

Marvin Lerousseau (M)

U1030 Molecular Radiotherapy, Paris-Sud University - Gustave Roussy - Inserm - Paris-Saclay University, Villejuif, France; Department of Medical Physics, Gustave Roussy - Paris-Saclay University, Villejuif, France; MICS Laboratory, CentraleSupélec, Paris-Saclay University, Gif-sur-Yvette, France.

Alexandre Carré (A)

U1030 Molecular Radiotherapy, Paris-Sud University - Gustave Roussy - Inserm - Paris-Saclay University, Villejuif, France; Department of Medical Physics, Gustave Roussy - Paris-Saclay University, Villejuif, France.

Roger Sun (R)

U1030 Molecular Radiotherapy, Paris-Sud University - Gustave Roussy - Inserm - Paris-Saclay University, Villejuif, France; Department of Medical Physics, Gustave Roussy - Paris-Saclay University, Villejuif, France; MICS Laboratory, CentraleSupélec, Paris-Saclay University, Gif-sur-Yvette, France; Department of Radiotherapy, Gustave Roussy - Paris-Saclay University, Villejuif, France.

Guillaume Klausner (G)

U1030 Molecular Radiotherapy, Paris-Sud University - Gustave Roussy - Inserm - Paris-Saclay University, Villejuif, France; Department of Radiotherapy, Gustave Roussy - Paris-Saclay University, Villejuif, France.

Samy Ammari (S)

Department of Radiology, Gustave Roussy - Paris-Saclay University, Villejuif, France.

Nathan Benzazon (N)

U1030 Molecular Radiotherapy, Paris-Sud University - Gustave Roussy - Inserm - Paris-Saclay University, Villejuif, France; Department of Medical Physics, Gustave Roussy - Paris-Saclay University, Villejuif, France.

Sylvain Reuzé (S)

U1030 Molecular Radiotherapy, Paris-Sud University - Gustave Roussy - Inserm - Paris-Saclay University, Villejuif, France; Department of Medical Physics, Gustave Roussy - Paris-Saclay University, Villejuif, France.

Théo Estienne (T)

U1030 Molecular Radiotherapy, Paris-Sud University - Gustave Roussy - Inserm - Paris-Saclay University, Villejuif, France; Department of Medical Physics, Gustave Roussy - Paris-Saclay University, Villejuif, France; MICS Laboratory, CentraleSupélec, Paris-Saclay University, Gif-sur-Yvette, France.

Stéphane Niyoteka (S)

U1030 Molecular Radiotherapy, Paris-Sud University - Gustave Roussy - Inserm - Paris-Saclay University, Villejuif, France; Department of Medical Physics, Gustave Roussy - Paris-Saclay University, Villejuif, France.

Enzo Battistella (E)

U1030 Molecular Radiotherapy, Paris-Sud University - Gustave Roussy - Inserm - Paris-Saclay University, Villejuif, France; Department of Medical Physics, Gustave Roussy - Paris-Saclay University, Villejuif, France; MICS Laboratory, CentraleSupélec, Paris-Saclay University, Gif-sur-Yvette, France.

Angéla Rouyar (A)

U1030 Molecular Radiotherapy, Paris-Sud University - Gustave Roussy - Inserm - Paris-Saclay University, Villejuif, France; Department of Medical Physics, Gustave Roussy - Paris-Saclay University, Villejuif, France.

Georges Noël (G)

Department of Radiotherapy, Paul Strauss Institute, Strasbourg, France.

Anne Beaudre (A)

Department of Medical Physics, Gustave Roussy - Paris-Saclay University, Villejuif, France.

Frédéric Dhermain (F)

Department of Radiotherapy, Gustave Roussy - Paris-Saclay University, Villejuif, France.

Eric Deutsch (E)

U1030 Molecular Radiotherapy, Paris-Sud University - Gustave Roussy - Inserm - Paris-Saclay University, Villejuif, France; Department of Radiotherapy, Gustave Roussy - Paris-Saclay University, Villejuif, France.

Nikos Paragios (N)

TheraPanacea, Paris, France.

Charlotte Robert (C)

U1030 Molecular Radiotherapy, Paris-Sud University - Gustave Roussy - Inserm - Paris-Saclay University, Villejuif, France; Department of Medical Physics, Gustave Roussy - Paris-Saclay University, Villejuif, France. Electronic address: ch.robert@gustaveroussy.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH